ZURICH (Reuters) - Swiss contract drug manufacturer Lonza received a key licence from Switzerland to produce ingredients for Moderna's COVID-19 vaccine, regulator Swissmedic said on Monday, a boost for a global inoculation program that has hit some snags.
The licence, for Lonza's new $70 million production line in Visp, Switzerland, dedicated to make ingredients for the Moderna vaccine, will help boost the U.S.-based company's deliveries to Europe, Canada and other nations outside the United States.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!